Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.5.0.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2016
Jun. 30, 2016
Current assets:    
Cash $ 20,098 $ 23,014
Accounts receivable - trade 170 484
Accounts receivable - unbilled 62 122
Work in process 0 22
Prepaid expenses and other current assets 132 264
Total Current Assets 20,462 23,906
Fixed assets, net of accumulated depreciation 25,580 25,574
Intangible assets, net of accumulated amortization 2,023 2,092
Security deposit 26 28
Total Assets 48,091 51,600
Current liabilities:    
Accounts payable (related party of $239 and $200 as of September 30, 2016 and June 30, 2016, respectively) 979 1,177
Accrued expenses (related party of $772 and $623 as of September 30, 2016 and June 30, 2016 respectively) 1,022 920
Capital lease obligation - current portion 173 170
Deferred revenue 0 24
Total Current Liabilities 2,174 2,291
Capital lease obligation - net of current portion 25,220 25,265
Total Liabilities 27,394 27,556
Commitments and Contingencies
iBio, Inc. Stockholders’ Equity:    
Preferred stock - no par value; 1,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock - $0.001 par value; 175,000,000 shares authorized; 89,109,410 shares issued and outstanding as of September 30, 2016 and June 30, 2016 89 89
Additional paid-in capital 67,733 67,468
Accumulated other comprehensive loss (29) (29)
Accumulated deficit (60,652) (57,591)
Total iBio, Inc. Stockholders’ Equity 7,141 9,937
Noncontrolling interest 13,556 14,107
Total Equity 20,697 24,044
Total Liabilities and Equity $ 48,091 $ 51,600